Concepedia

Kyle A. Beckwith

KA

12

Publications

2.1K

Citations

12

H-Index

2013

Active since

Affiliations

The Ohio State University(Current)

Massachusetts General Hospital

Harvard University

University of Pennsylvania

National Student Clearinghouse Research Center

Kyle A. Beckwith is an author at The Ohio State University specializing in cell biology, immunology, and medicine.

ORCID

Top concepts

Publications per year

2013–2022

12

Publications

12

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 783 citations · Full text

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel et al. · Blood · 2016 · 450 citations · Full text

Ibrutinib treatment improves T cell number and function in CLL patients

Meixiao Long, Kyle A. Beckwith, Priscilla Do et al. · Journal of Clinical Investigation · 2017 · 362 citations · Full text

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Zachary A. Hing, Rose Mantel, Kyle A. Beckwith et al. · Blood · 2015 · 91 citations · Full text

Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages

John C. Gensel, Yan Wang, Zhen Guan et al. · Journal of Neuroscience · 2015 · 75 citations · Full text

Rows per page

1–5 of 12